Showing results (191-200 of 321) with videos related to

Sort By:
Pageof 33
Plos One|May 24, 2014
SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford studyErfan Aref-Eshghi, Yuhua Zhang, Deborah Hart, et al.
Rheumatology (Oxford, England)|September 7, 2014
Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosusTimothy Li, Stephenie D Prokopec, Stacey Morrison, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Blood|December 14, 2002
Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interactionChristopher Butt, Hong Zheng, Edward Randell, et al.
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
Arthritis Care & Research|June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III TrialArthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
Annals of the Rheumatic Diseases|May 7, 2021
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)Robert Bm Landewé, Lianne S Gensler, Denis Poddubnyy, et al.
Rheumatology and Therapy|September 19, 2025
Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian SettingRegan Arendse, Proton Rahman, Philip Baer, et al.
Rheumatology and Therapy|February 28, 2024
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE StudyVinod Chandran, Louis Bessette, Carter Thorne, et al.
The Journal of Rheumatology|April 19, 2011
The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritisDafna D Gladman, Proton Rahman, Richard J Cook, et al.
Pageof 33